System and method for performing surgical procedures with a reusable instrument module

File for Quick & Easy Patent Protection with PowerPatent.

The Covidien Lp patent solves the following problem:

The present disclosure relates generally to the field of reposable or reusable opera. In particular, the disclosure relates to instruments with separable and replaceable components to provide clean, sterile or renovated over time.

Our analysis of this patent is as follows:

Covidien Lp’s patent US 9456873 B2 deals with System and method for performing surgical procedures with a reusable instrument module.
A surgical instrument includes an outer housing shell defining a cavity. The outer housing shell defines an upper outer housing half and a lower outer housing of the half. The upper outer housing half defines a longitudinal axis. An instrument module is selectively insertable into the hole in the outer housing shell. The instrument module includes an inner housing shell, at least one motor disposed in the housing shell, a control board in electrical communication with at least one motor, and an energy source in electrical communication with at least one motor and the control board. The instrument module is inserted into the hole in the outer housing shell in such a way that the operative axis at least one motor that substantially parallel to the longitudinal axis on the outer half of the housing.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Particle separator for an air conduit, air distribution system, use of a particle separator and aircraft

File for Quick & Easy Patent Protection with PowerPatent.

The Airbus Operations Gmbh, , Diehl Aircabin Gmbh patent solves the following problem:

For the provision of a climate on board a commercial plane, climate agreeable passengers, usually an air conditioning system that uses the guiding conditioned air through a multitude of air outlets into a passenger cabin. In some cases the operating relatively high outside temperatures and a high atmospheric humidity of the surrounding air is controlled, the air conditioning packs to eject ice collected in neighboring profit system of air distribution. To prevent pressure loss in the pipes, often ice cyclically defrosted, where there is more ice accumulation can be separated from the pipe. When impacting the bottom wall of the pipe, ice accumulation decompose into small pieces and find his way as ice particles through the air outlets into the passenger cabin. The size of the ice particles estimated to be compared to the hail.

Our analysis of this patent is as follows:

Airbus Operations Gmbh, , Diehl Aircabin Gmbh’s patent US 9457303 B2 deals with Particle separator for an air conduit, air distribution system, use of a particle separator and aircraft.
A particle separator consists of a pipeline that allows a fluid to flow in a curved direction of the flow. The particle separator includes a head region, a curved deflection region, in the direction of the flow following from the mouth region, with an inside wall and an outside wall, and a delimitation body. The delimitation body at least in certain sections provided between the inner wall and the outer wall in the deflection region and curved in the same direction as the deflection region.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for producing enteroendocrine cells that make and secrete insulin

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Trustees Of Columbia University In The City Of New York patent solves the following problem:

Methods for treating and preventing type 1 and 2 diabetes.

Our analysis of this patent is as follows:

The Trustees Of Columbia University In The City Of New York’s patent US 9457079 B2 deals with Methods for producing enteroendocrine cells that make and secrete insulin.
Methods described in enteroendocrine cells and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo protein or biologically active fragments or race.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibody induced cell membrane wounding

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Igm Biosciences, Inc. patent solves the following problem:

Cell membrane wounding is a disruption in the plasma membrane of cells, and in general a surviving the incident. Cell membrane strike is a common occurrence in mammal mechanically active tissues such as endothelial lining of the aorta or the gastrointestinal tract, skin epithelia or myocytes in the heart or skeletal muscles, and also shown during the invasion of cells in trypanosomes. In laboratory conditions, cell wounding normally induced using mechanical means to bind to the cell membrane, such as using a Microneedle to penetrate the plasma membrane or by scratching a culture dish to differentiate one part of a cell.

Our analysis of this patent is as follows:

Igm Biosciences, Inc.’s patent US 9458241 B2 deals with Antibody induced cell membrane wounding.
Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell death gave. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. At best, the cell surface antigen with the cell cytoskeleton. A preferred polyvalent agent is an IgM, and enhanced cell wounding and murder will be given to the addition of a crosslinking agent. Sublethal concentration in vivo, the cell wounding antibody permeabilize cells and dramatically improve the response to chemotherapeutic agents, even in patients rebelled chemotherapeutic agents.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Surgical apparatus and structure for applying sprayable wound treatment material

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Covidien Lp patent solves the following problem:

The present disclosure relates to surgical instruments and methods for enhancing properties of tissue repaired or joined the surgical food and, especially in facilities and operations structure configured to use the mechanical surgical fasteners and / or a non- mechanical biocompatible wound treatment material to improve the properties of fixing or adjacent tissue at a target surgical site.

Our analysis of this patent is as follows:

Covidien Lp’s patent US 9456821 B2 deals with Surgical apparatus and structure for applying sprayable wound treatment material.
According to one aspect of the present disclosure, an apparatus for forming an anastomosis between adjacent tissue sections provided. apparatus includes a body portion; an actuation assembly operatively supported at a proximal end of the body; anvil assembly movably mounted on the distal end of the body portion for movement in and out of the body; an estimated congregation came between the body and the anvil assembly for moving the anvil into and out of the tubular body portion; a dispersion assembly operatively associated with the approximation assembly, the dispersion assembly including at least one angled surface defining at least one channel interposed between the anvil assembly and the body portion and configured to dispense a fluid; and at least one conduit for conducting wound treatment material dispersion assembly.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Cancer Research Technology Limited patent solves the following problem:

With more than 800 members, G-protein-coupled receptor (GPCRs) represent the largest family of cell surface molecules involved in signal transmission, accounting for 2% of the total gene encoded human genome. The members of the GPCR share a common membrane Topology: an extracellular N-terminus, an intracellular C-terminus and seven transmembrane (TM) helices connected by three intracellular loops and three extracellular loops. On the basis of their shared topological structure, GPCRs are also referred to as seven transmembrane (7tm) receptor. These receptors control key physiological functions, including neurotransmission, hormone and enzyme release from endocrine and exocrine glands, immune responses, cardiac- and smooth-muscle and blood pressure regulation. Their dysfunction contributes to some of the most widespread human diseases. Emerging experimental and clinical data showed that GPCRs have an important role in cancer growth and metastasis. Therefore, the possibility exists that some GPCRs could be target for anti-cancer drugs.

Our analysis of this patent is as follows:

Cancer Research Technology Limited’s patent US 9458238 B2 deals with Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof.
The present invention provides antibodies that bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and that is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) CCR4. Also provides inter alia immunoconjugates and compositions comprising these antibodies and methods and uses involving the same antibody, particularly in the medical and diagnostic fields.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modified DNA-binding proteins and uses thereof

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Sangamo Biosciences, Inc. patent solves the following problem:

Transcription Activator Effector-like protein (story) is the protein encoded in the phytopathogenic bacteria of the genus Xanthomonas and Ralstonia influence gene expression in the host plant cells during bacterial infection. These proteins contain a DNA binding region and an A-terminal domain that appears to interact with bacteria in transport machinery to make proteins in plant cells. The C-terminal domain of the protein story seems to interact with the transcriptional machinery in the plant's army to induce expression of the gene set of plants useful to the invading bacteria. The DNA binding of the protein found in the middle section of the protein and made an array of repeated units, each approximately 33-35 amino acid long-on, which is shown to be responsible for association with the target DNA.

Our analysis of this patent is as follows:

Sangamo Biosciences, Inc.’s patent US 9458205 B2 deals with Modified DNA-binding proteins and uses thereof.
Expressed in enhanced polypeptides, polynucleotides encoding these polypeptides, cells and organisms that contain novel DNA-binding domain, including the story of DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and / or genomic editing of the endogenous cellular sequences.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Subcutaneous biopsy cavity marker device

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Devicor Medical Products, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Devicor Medical Products, Inc.’s patent US 9456878 B2 deals with Subcutaneous biopsy cavity marker device.
A marking device for identifying a subcutaneous biopsy hole with a first nonabsorbable label elements detected by a first imaging modality and a second nonabsorbable label elements detected by a second imaging modality but not observed in the first imaging modality.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Golf aid including heads up display

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Nike, Inc. patent solves the following problem:

The game of golf is a popular sport at both amateur and professional levels. Both amateur and professional golfers spend large amounts of time to develop muscle memory and fine motor skills needed to improve their game. Golfers try to improve their game by analyzing launch and trajectory information while playing golf. Golf balls are sometimes difficult to see when flying in the air on a golf course. Therefore, it can be difficult to monitor the trajectory of a golf ball and find the golf balls after they landed. Therefore, it is useful to provide a system for tracking a golf ball.

Our analysis of this patent is as follows:

Nike, Inc.’s patent US 9457246 B2 deals with Golf aid including heads up display.
A golf aid includes a user tracking system configured to determine the location of a user on a golf course, a processor, and a display head. The heads of the display is configured to be worn on the user's head, and the display of an image in a field of view of the user. processor is in communication with the tracking system user and with the heads of the display, and configured to determine a distance between the location of the user and a thing, and give a indication of the determined distance to the user through the display head.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genmab A/S patent solves the following problem:

The EGF receptor (EGFR) is a 170 kDa type 1 transmembrane molecules. The expression found upregulated in many human tumors including carcinoma of the head and neck, breast, colon, prostate, lung, and ovaries. The kind of over-expression correlated with poor clinical prognosis (Baselga, et al (1994) Pharmac therapeut 64: ….. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296). Furthermore, his expression always accompanied by the production of EGFR ligands, TGF- and EGF among others, by EGFR-expressing tumor cells suggests that an autocrine loop participates in growth this cells (Baselga, et al. (1994) Pharmac therapeut 64: …. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296) .. Ali interaction between such EGFR ligands and EGFR therefore can inhibit tumor growth and survival (Baselga, et al (1994) Pharmac therapeut 64: 127-154).

Our analysis of this patent is as follows:

Genmab A/S’s patent US 9458236 B2 deals with Human monoclonal antibodies to epidermal growth factor receptor (EGFR).
Isolated human monoclonal antibody that specifically binds to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibody can be produced in a transfectoma or a non-human transgenic animals, for example, a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing VDJ recombination and isotype switch. also discloses pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas that produce human antibodies, and therapeutic and diagnostic methods using human antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.